The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Roth thinks Capricor Therapeutics drug could still be approved by August 31
- Adobe reports Q2 beat, Meta invests in Scale AI: Morning Buzz
- H.C. Wainwright cautions Capricor investors to ‘calm down’ after FDA letter
- Capricor Therapeutics put volume heavy and directionally bearish
- Capricor weakness attributed to FDA letter on advisory meeting